NKCx Histopathological outcome* within 12 months after cervix cytology in 2021 |
251 Kalmar |
Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
Benign sample | 193 | 2.5% | 195 | 2.5% | 31 | 0.4% | 1 | 0.0% | 2 | 0.0% | 112 | 1.4% | 7215 | 93.1% | 7749 | 100.0% |
ASCUS | 48 | 9.4% | 134 | 26.3% | 37 | 7.3% | 1 | 0.2% | . | . | 54 | 10.6% | 235 | 46.2% | 509 | 100.0% |
LSIL | 47 | 9.3% | 174 | 34.5% | 84 | 16.6% | . | . | . | . | 42 | 8.3% | 158 | 31.3% | 505 | 100.0% |
Atypical glandular cells/AGC | 3 | 17.6% | 5 | 29.4% | 1 | 5.9% | 2 | 11.8% | . | . | 3 | 17.6% | 3 | 17.6% | 17 | 100.0% |
Unclear atypia | 4 | 10.0% | 15 | 37.5% | 11 | 27.5% | . | . | 2 | 5.0% | 4 | 10.0% | 4 | 10.0% | 40 | 100.0% |
ASC-H | 1 | 0.8% | 18 | 13.8% | 105 | 80.8% | . | . | . | . | 2 | 1.5% | 4 | 3.1% | 130 | 100.0% |
HSIL | 2 | 2.0% | 10 | 10.0% | 81 | 81.0% | . | . | 1 | 1.0% | 2 | 2.0% | 4 | 4.0% | 100 | 100.0% |
Suspected Adenocarcinom | . | . | . | . | . | . | 2 | 33.3% | 1 | 16.7% | . | . | 3 | 50.0% | 6 | 100.0% |
Malignant tumor with unclear origin | . | . | . | . | . | . | . | . | 3 | 60.0% | . | . | 2 | 40.0% | 5 | 100.0% |
Squamous cell cancer | . | . | . | . | . | . | . | . | 2 | 66.7% | . | . | 1 | 33.3% | 3 | 100.0% |
Totalt | 298 | 3.3% | 551 | 6.1% | 350 | 3.9% | 6 | 0.1% | 11 | 0.1% | 219 | 2.4% | 7629 | 84.2% | 9064 | 100.0% |
NOTE: Histopathological outcome from T83x taken into account. |
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
Snomed codes in the category Cancer: |
---|
M69760, M80109, M80703, M81403, M81409 |